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Immunotherapy can paradoxically up-regulate immuno-
suppressive pathways, a phenomenon we term “rebound
immunosuppression”. One such pathway is the immu-
nosuppressive enzyme indolamine-2,3-dioxygenase
(IDO). Here, we postulated that IDO blockade will
improve immunotherapy efficacy by preventing rebound
immune-suppression. It has been previously shown that
immunotherapy consisting of intralesional CpG and
radiotherapy can induce objective systemic responses
but that patients whose tumors induce regulatory Tregs
are unlikely to respond. We suggest that IDO induced
rebound immune suppression limits the effectiveness of
this combination by preventing rebound immune sup-
pression. In tumor-bearing mice, local IDO expression
markedly increased after treatment with local radiother-
apy + intratumoral CpG or other immunotherapies. The
addition of IDO blockade to radiotherapy + CpG
decreased IDO expression and activity, reduced tumor
growth, and reduced immunosuppressive factors, includ-
ing Tregs, in the tumor microenvironment but not sys-
temically. This triple combination did induce systemic
anti-tumor effects decreasing metastases and improving
survival in a CD8+ T cell dependent manner. IDO
blockade and/or CPG were ineffective without radio-
therapy. We evaluated this novel triple therapy in a
canine clinical trial, since spontaneous canine malignan-
cies closely reflect human cancer. Mirroring the results
in mice, therapy was well tolerated, reduced local tumor
immunosuppression, and induced robust systemic anti-
tumor effects. Disease response or stability was observed
in 80% of dogs with previously rapidly progressing
disease. These results suggest IDO up-regulation in the
tumor micro-environment maintains immunosuppres-
sion after immunotherapy. IDO blockade may improve
treatment efficacy by limiting this rebound immune-
suppression, allowing the local tumor to initiate a sys-
temic anti-tumor immune response. The efficacy and
limited toxicity of this strategy are attractive for clinical
translation.
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